Logo
Homepage
Explore Our Models
My Cart
Contact
Subscribe
Models
Genetically Engineered Animals
Knockout Mice
Knockout Rats
Knockin Mice
Knockin Rats
Transgenic Mice
Transgenic Rats
Model Generation Techniques
Turboknockout<sup>®</sup> Gene Targeting
ES Cell Gene Targeting
Targeted Gene Editing
Regular Transgenic
PiggyBac Transgenesis
BAC Transgenic
Research Models
HUGO-GT™ Humanized Mice
Cre Mouse Lines
Humanized Target Gene Models
Metabolic Disease Models
Ophthalmic Disease Models
Neurological Disease Models
Autoimmune Disease Models
Immunodeficient Mouse Models
Humanized Immune System Mouse Models
Oncology & Immuno-oncology Models
Covid-19 Mouse Models
MouseAtlas Model Library
Knockout Cell Line Product Catalog
Tumor Cell Line Product Catalog
AAV Standard Product Catalog
Animal Supporting Services
Breeding Services
Cryopreservation & Recovery
Phenotyping Services
BAC Modification
Custom Cell Line Models
Induced Pluripotent Stem Cells (iPSCs)
Knockout Cell Lines
Knockin Cell Lines
Point Mutation Cell Lines
Overexpression Cell Lines
Virus Packaging
Adeno-associated Virus (AAV) Packaging
Lentivirus Packaging
Adenovirus Packaging
CRO Services
By Therapeutic Area
Oncology
Ophthalmology
Neuroscience
Metabolic & Cardiovascular Diseases
Autoimmune & Inflammatory
By Drug Type
AI-Powered AAV Discovery
Gene Therapy
Oligonucleotide Therapy
Antibody Therapy
Cell Immunotherapy
Resources
Promotion
Events & Webinars
Newsroom
Blogs & Insights
Resource Vault
Reference Databases
Peer-Reviewed Citations
Rare Disease Data Center
AbSeek
Cell iGeneEditor™ System
OriCell
Quality
Facility Overview
Animal Health & Welfare
Health Reports
About Us
Corporate Overview
Our Partners
Careers
Contact Us
Login
Request a Product Quote
Select products from our catalogs and submit your request. Our team will get back to you with detailed information.
Full Name
Email
Phone Number
Organization
Job Role
Country
Catalog Type
Product Name
Additional Comments
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
C57BL/6JCya-Atp1a1em1flox/Cya
Common Name:
Atp1a1-flox
Product ID:
S-CKO-17558
Background:
C57BL/6JCya
Product Type
Age
Genotype
Sex
Quantity
Price:
Contact for Pricing
Basic Information
Strain Name
Atp1a1-flox
Strain ID
CKOCMP-11928-Atp1a1-B6J-VC
Gene Name
Atp1a1
Product ID
S-CKO-17558
Gene Alias
Atpa-1
Background
C57BL/6JCya
NCBI ID
11928
Modification
Conditional knockout
Chromosome
3
Phenotype
MGI:88105
Document
Click here to download >>
Application
--
More
Rare Disease Data Center >>
Note
Note: When using this mouse strain in a publication, please cite “C57BL/6JCya-Atp1a1em1flox/Cya mice (Catalog S-CKO-17558) were purchased from Cyagen.”
Strain Description
Ensembl Number
ENSMUST00000036493
NCBI RefSeq
NM_144900
Target Region
Exon 8
Size of Effective Region
~0.7 kb
Detailed Document
Click here to download >>
Overview of Gene Research
Atp1a1, encoding the α1 subunit of the Na+/K+-ATPase (NKA), is a crucial gene. The NKA heterodimeric enzyme hydrolyzes ATP to establish transmembrane electrochemical gradients of Na+ and K+, which are essential for electrical signaling and cell survival. The α1 isoform is ubiquitously expressed and is the predominant paralog in peripheral axons [4,9].

Mutations in Atp1a1 have been linked to multiple diseases. In aldosterone-producing adenomas (APAs), the ATP1A1 L104R mutation leads to increased Na/K-ATPase (NKA) expression, stimulating cell proliferation and Src phosphorylation, suggesting NKA stimulations as a risk factor for APA development [1]. In intermediate Charcot-Marie-Tooth (CMT) disease, two novel missense mutations in ATP1A1 were identified, causing loss-of-function of the ATP1A1 protein through promoting its proteasome degradation [2]. A heterozygous ATP1A1 variant Gly903Arg causes developmental delay, intellectual disability, and autism, with reduced cell viability and loss of ATPase function [3]. De novo mutations in ATP1A1 are related to disorders with phenotypes like developmental delay, epilepsy, and hypomagnesemia, and mutations in different transmembrane regions of the ATP1A1 protein result in different severities of phenotypes [5]. In melanoma, high ATP1A1 expression is associated with reduced overall survival and resistance to BRAF inhibitor, and its ligand bufalin can target ATP1A1 to inhibit cell proliferation and tumor growth [6]. In myelomonocytic and monocytic acute myeloid leukemia, the ATP1A1/BCL2L1 expression ratio predicts the response to cardiac glycosides [7]. Also, somatic mutations in ATP1A1 are found in over 90% of aldosterone-producing adenomas [8].

In conclusion, Atp1a1 is essential for maintaining transmembrane electrochemical gradients via encoding the α1 subunit of NKA. Research on Atp1a1-related mutations in various disease models, such as those in APAs, CMT, and developmental disorders, has revealed its role in cell proliferation, neurological functions, and disease-associated phenotypes. These findings contribute to understanding the pathogenesis of related diseases and potentially developing new therapeutic strategies.

References:
1. Kobuke, Kazuhiro, Oki, Kenji, Gomez-Sanchez, Celso E, Hattori, Noboru, Yoneda, Masayasu. 2021. ATP1A1 Mutant in Aldosterone-Producing Adenoma Leads to Cell Proliferation. In International journal of molecular sciences, 22, . doi:10.3390/ijms222010981. https://pubmed.ncbi.nlm.nih.gov/34681640/
2. He, Jin, Guo, Lingling, Lin, Shan, Wang, Ning, Chen, Wanjin. 2019. ATP1A1 mutations cause intermediate Charcot-Marie-Tooth disease. In Human mutation, 40, 2334-2343. doi:10.1002/humu.23886. https://pubmed.ncbi.nlm.nih.gov/31373411/
3. Dohrn, Maike F, Bademci, Guney, Rebelo, Adriana P, Tekin, Mustafa, Züchner, Stephan. 2024. Recurrent ATP1A1 variant Gly903Arg causes developmental delay, intellectual disability, and autism. In Annals of clinical and translational neurology, 11, 1075-1079. doi:10.1002/acn3.51963. https://pubmed.ncbi.nlm.nih.gov/38504481/
4. Spontarelli, Kerri, Young, Victoria C, Sweazey, Ryan, Yano, Sho T, Artigas, Pablo. 2023. ATP1A1 -linked diseases require a malfunctioning protein product from one allele. In bioRxiv : the preprint server for biology, , . doi:10.1101/2023.03.05.531165. https://pubmed.ncbi.nlm.nih.gov/37090550/
5. Lin, Zehong, Li, Jinliang, Ji, Taoyun, Gao, Kai, Jiang, Yuwu. 2021. ATP1A1 de novo Mutation-Related Disorders: Clinical and Genetic Features. In Frontiers in pediatrics, 9, 657256. doi:10.3389/fped.2021.657256. https://pubmed.ncbi.nlm.nih.gov/33968856/
6. Soumoy, Laura, Genbauffe, Aline, Mouchart, Lena, Saussez, Sven, Journe, Fabrice. 2024. ATP1A1 is a promising new target for melanoma treatment and can be inhibited by its physiological ligand bufalin to restore targeted therapy efficacy. In Cancer cell international, 24, 8. doi:10.1186/s12935-023-03196-y. https://pubmed.ncbi.nlm.nih.gov/38178183/
7. Cerella, Claudia, Gajulapalli, Sruthi Reddy, Lorant, Anne, Dicato, Mario, Diederich, Marc. 2023. ATP1A1/BCL2L1 predicts the response of myelomonocytic and monocytic acute myeloid leukemia to cardiac glycosides. In Leukemia, 38, 67-81. doi:10.1038/s41375-023-02076-8. https://pubmed.ncbi.nlm.nih.gov/37904054/
8. Scholl, Ute I. 2022. Genetics of Primary Aldosteronism. In Hypertension (Dallas, Tex. : 1979), 79, 887-897. doi:10.1161/HYPERTENSIONAHA.121.16498. https://pubmed.ncbi.nlm.nih.gov/35139664/
9. Spontarelli, Kerri, Young, Victoria C, Sweazey, Ryan, Yano, Sho T, Artigas, Pablo. 2023. ATP1A1-linked diseases require a malfunctioning protein product from one allele. In Biochimica et biophysica acta. Molecular cell research, 1871, 119572. doi:10.1016/j.bbamcr.2023.119572. https://pubmed.ncbi.nlm.nih.gov/37659504/
Quality Control Standard
Sperm Test

Pre-cryopreservation: Measurement of sperm concentration, determination of sperm viability.

Post-cryopreservation: A vial of cryopreserved sperms is selected for in-vitro fertilization from each batch.

Environmental Standards:SPF
Available Region:Global
Source:Cyagen
Model Library
Model Library
Resources
Resources
Animal Quality
Animal Quality
Get Support
Get Support
Address:
2255 Martin Avenue, Suite E Santa Clara, CA 95050-2709, US
Tel:
800-921-8930 (8-6pm PST)
+1408-963-0306 (lnt’l)
Fax:
408-969-0338
Email:
animal-service@cyagen.com
service@cyagen.us
CRO Services
OncologyOphthalmologyNeuroscienceMetabolic & CardiovascularAutoimmune & InflammatoryGene TherapyAntibody Therapy
About Us
Corporate OverviewOur PartnersCareersContact Us
Social Media
Disclaimer: Pricing and availability of our products and services vary by region. Listed prices are applicable to the specific countries. Please contact us for more information.
Copyright © 2025 Cyagen. All rights reserved.
Privacy Policy
Site Map
Stay Updated with the Latest from Cyagen
Get the latest news on our research models, CRO services, scientific resources, and special offers—tailored to your research needs and delivered straight to your inbox.
Full Name
Email
Organization
Country
Areas of Interest